Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis
Open Access
- 1 May 2009
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American Society of Nephrology
- Vol. 20 (5), 1103-1112
- https://doi.org/10.1681/asn.2008101028
Abstract
Recent studies have suggested that mycophenolate mofetil (MMF) may offer advantages over intravenous cyclophosphamide (IVC) for the treatment of lupus nephritis, but these therapies have not been compared in an international randomized, controlled trial. Here, we report the comparison of MMF and IVC as induction treatment for active lupus nephritis in a multinational, two-phase (induction and maintenance) study. We randomly assigned 370 patients with classes III through V lupus nephritis to open-label MMF (target dosage 3 g/d) or IVC (0.5 to 1.0 g/m2 in monthly pulses) in a 24-wk induction study. Both groups received prednisone, tapered from a maximum starting dosage of 60 mg/d. The primary end point was a prespecified decrease in urine protein/creatinine ratio and stabilization or improvement in serum creatinine. Secondary end points included complete renal remission, systemic disease activity and damage, and safety. Overall, we did not detect a significantly different response rate between the two groups: 104 (56.2%) of 185 patients responded to MMF compared with 98 (53.0%) of 185 to IVC. Secondary end points were also similar between treatment groups. There were nine deaths in the MMF group and five in the IVC group. We did not detect significant differences between the MMF and IVC groups with regard to rates of adverse events, serious adverse events, or infections. Although most patients in both treatment groups experienced clinical improvement, the study did not meet its primary objective of showing that MMF was superior to IVC as induction treatment for lupus nephritis.Keywords
This publication has 34 references indexed in Scilit:
- A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLEArthritis Care & Research, 2007
- Update on the treatment of lupus nephritisKidney International, 2006
- Outcomes in African Americans and Hispanics with lupus nephritisKidney International, 2006
- An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a 25-year periodRheumatology, 2006
- Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritisArthritis Research & Therapy, 2006
- Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus NephritisThe New England Journal of Medicine, 2005
- Prospective Registry‐Based Observational Cohort Study of the Long‐Term Risk of Malignancies in Renal Transplant Patients Treated with Mycophenolate MofetilAmerican Journal of Transplantation, 2005
- Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritisNephrology, 2005
- Ovarian failure and strategies for fertility preservation in patients with systemic lupus erythematosusLupus, 2004
- Clinical and Immunologic Effects of Monthly Administration of Intravenous Cyclophosphamide in Severe Systemic Lupus ErythematosusThe New England Journal of Medicine, 1988